Spectrum Pharmaceutecals Inc (SPPI)

[dcaf7]

Korean analyst on Rolvedon

Published 2023.03.03 18:33

Hanmi Pharm's R&D prowess is also being proven in the U.S. with Rolvedon.

Rolvedon is Hanmi's first new biologic drug that is used to treat or prevent severe neutropenia in cancer patients who have undergone chemotherapy.

The drug is the first product to receive marketing approval by applying Hanmi's proprietary platform technology, "LAPSCOVERY," which boosts a bio-medicine's efficacy.

Hanmi had previously licensed out the treatment to Spectrum Pharmaceuticals, its U.S. partner, in 2012, and Spectrum received approval in September of last year.

Notably, there is additional hype surrounding the success of Rolvedon as it recently got listed on the U.S. public insurance reimbursement drug list.

Industry watchers expect that the listing will have a positive impact on expanding prescriptions and establishing brand awareness as the cost burden of patients is lowered.

Local analysts also expect good performance from Rolvedon this year.

"Spectrum estimation Rolvedon's sales in the fourth quarter of last year was $10 million," said Ha Hyeon-soo, an analyst at Yuanta Securities. "The drug's sales target this year is $100 million as the top three community oncology networks in the U.S. started using Rolvedon, and the three communities account for about 22 percent of the total clinic market."
https://www.koreabiomed.com/news/articleView.html?idxno=20574